1 recruiting, 1 unknown. 2 Phase 2, 1 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Recruiting 1, Unknown 1 |
| Phase 1 | 1 | Recruiting 1 |
| Phase 3 | 1 | Unknown 1 |
Follow Autoimmune Rheumatologic Disease: new trials by email Literature Review of Autoimmune Rheumatologic Disease trials Research Report on Autoimmune Rheumatologic Disease
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Controlling Hyperactive Immunity With Long-lived Lymphocytes QEL-005 - Diffuse Cutaneous Systemic Sclerosis, Rheumatoid Arthritis (RA) | Phase 1 / Phase 2 | Recruiting | Quell Therapeutics Limited | 16 | 2026-04-10 | 2026-10-19 |
| COvid-19 Vaccine Booster in Immunocompromised Rheumatic Diseases COVID-19 vaccine - Rheumatoid Arthritis, Autoimmune Rheumatologic Disease | Phase 2 / Phase 3 | Unknown | Paul R Fortin | 287 | 2022-03-09 | 2023-01-17 |
Arthritis, Rheumatoid (2) · Scleroderma, Diffuse (2) · Scleroderma, Systemic (2) · Lupus Erythematosus, Systemic (1) · MASS syndrome (1) · Systemic Vasculitis (1) · Undifferentiated Connective Tissue Diseases (1)
Arthritis (2) · Autoimmune Diseases (2) · Connective Tissue Diseases (2) · Immune System Diseases (2) · Joint Diseases (2) · Musculoskeletal Diseases (2) · Rheumatic Diseases (2) · Skin Diseases (2) · Skin and Connective Tissue Diseases (2) · Cardiovascular Diseases (1) · Vascular Diseases (1) · Vasculitis (1)
Paul R Fortin (1) · Quell Therapeutics Limited (1)
Canada (1) · Germany (1) · Spain (1) · United Kingdom (1)
Paul R Fortin, MD,MPH,FRCPC (1)
2025 (1)